Randomized, Phase III-b, Multi-Centre, Open-Label, Parallel Study of Enoxaparin (Low Molecular Weight Heparin) Given Concomitantly With Chemotherapy [antineoplastics] vs [versus] Chemotherapy Alone in Patients With Inoperable Gastric and Gastro-Oesophageal Cancer.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enoxaparin sodium (Primary) ; Capecitabine; Carboplatin; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Granulocyte colony-stimulating factors; Oxaliplatin
Indications Gastric cancer; Oesophageal cancer
Focus Therapeutic Use
Acronyms GASTRANOX

Most Recent Events

13 May 2015 Biomarkers information updated
30 Dec 2010 New source identified and integrated (Clinical Trials Registry - India record; CTRI2009-091-000885).
30 Dec 2010 Additional lead trial investigator identified as reported by Clinical Trials Registry - India record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight